These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10986219)

  • 21. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
    Bai M; Yang Z; Qi X; Fan D; Han G
    J Gastroenterol Hepatol; 2013 May; 28(5):783-92. PubMed ID: 23425108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
    Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
    Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease.
    Butterworth RF; Canbay A
    Dig Dis; 2019; 37(1):63-68. PubMed ID: 30016770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study.
    Acharya SK; Bhatia V; Sreenivas V; Khanal S; Panda SK
    Gastroenterology; 2009 Jun; 136(7):2159-68. PubMed ID: 19505424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.
    Sidhu SS; Sharma BC; Goyal O; Kishore H; Kaur N
    Hepatology; 2018 Feb; 67(2):700-710. PubMed ID: 28749571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
    Kircheis G; Lüth S
    Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration.
    Plauth M; Roske AE; Romaniuk P; Roth E; Ziebig R; Lochs H
    Gut; 2000 Jun; 46(6):849-55. PubMed ID: 10807899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Butterworth RF; Kircheis G; Hilger N; McPhail MJW
    J Clin Exp Hepatol; 2018 Sep; 8(3):301-313. PubMed ID: 30302048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
    Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
    Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
    He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
    Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normal protein diet and L-ornithine-L-aspartate for hepatic encephalopathy.
    Ndraha S; Simadibrata M
    Acta Med Indones; 2010 Jul; 42(3):158-61. PubMed ID: 20724770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience.
    Masson S; Mardini HA; Rose JD; Record CO
    QJM; 2008 Jun; 101(6):493-501. PubMed ID: 18440957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients.
    Masini A; Efrati C; Merli M; Nicolao F; Amodio P; Del Piccolo F; Riggio O
    Metab Brain Dis; 2003 Mar; 18(1):27-35. PubMed ID: 12603080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
    Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS.
    Gioia S; Merli M; Nardelli S; Lattanzi B; Pitocchi F; Ridola L; Riggio O
    Liver Int; 2019 May; 39(5):871-877. PubMed ID: 30667572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain regional homogeneity changes following transjugular intrahepatic portosystemic shunt in cirrhotic patients support cerebral adaptability theory--a resting-state functional MRI study.
    Ni L; Qi R; Zhang LJ; Zhong J; Zheng G; Wu X; Fan X; Lu GM
    Eur J Radiol; 2014 Mar; 83(3):578-83. PubMed ID: 24299611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
    Jain A; Sharma BC; Mahajan B; Srivastava S; Kumar A; Sachdeva S; Sonika U; Dalal A
    Hepatology; 2022 May; 75(5):1194-1203. PubMed ID: 34822189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
    Jiang Q; Jiang XH; Zheng MH; Chen YP
    J Gastroenterol Hepatol; 2009 Jan; 24(1):9-14. PubMed ID: 18823442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy.
    Riggio O; Mannaioni G; Ridola L; Angeloni S; Merli M; Carlà V; Salvatori FM; Moroni F
    Am J Gastroenterol; 2010 Jun; 105(6):1374-81. PubMed ID: 20125128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
    Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
    J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.